Cagrilintide/semaglutide
REDEFINE 2
Novo Nordisk · Phase 3 · Completed · Enrollment 1200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CagriSema | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Cagrilintide/semaglutide
Novo Nordisk · Phase 3 · Completed · Enrollment 1200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CagriSema | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |